VENU MADHAV KONALA
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
- Where
- DOUGLASVILLE, GA
- NPI
- 1164752952
- Received
- $114,346 in 204 records, 2019 to 2025 ($29,216 general, $85,129 research)
- As principal investigator
- $396,567 of research payments to others in 23 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 72 | $5,115 |
| 2024 | General payment | 94 | $15,994 |
| 2023 | General payment | 18 | $1,445 |
| 2022 | General payment | 3 | $653 |
| 2021 | General payment | 7 | $4,175 |
| 2020 | General payment | 5 | $1,660 |
| 2019 | General payment | 4 | $171 |
| 2019 | Research payment | 1 | $85,129 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 1 | $85,129 |
| Consulting Fee | 25 | $21,107 |
| Food and Beverage | 163 | $4,167 |
| Honoraria | 4 | $2,260 |
| Travel and Lodging | 8 | $1,298 |
| Grant | 1 | $350 |
| Education | 2 | $34 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-22 | Merck Sharp & Dohme LLC | $29 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-12-19 | Incyte Corporation | $23 | Food and Beverage | Cash or cash equivalent | MONJUVI Drug, Oncology | 2025 | |
| 2025-12-08 | Boehringer Ingelheim Pharmaceuticals, Inc. | $23 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-12-03 | ABBVIE INC. | $34 | Food and Beverage | In-kind items and services | EPKINLY Drug, ONCOLOGY | 2025 | |
| 2025-11-25 | GlaxoSmithKline, LLC. | $24 | Food and Beverage | In-kind items and services | BLENREP Biological, ONCOLOGY | 2025 | |
| 2025-11-21 | Genmab U.S., Inc. | $1,575 | Consulting Fee | In-kind items and services | Epkinly Drug, Oncology | 2025 | |
| 2025-11-18 | Novartis Pharmaceuticals Corporation | $29 | Food and Beverage | In-kind items and services | Fabhalta Drug, Immunology | 2025 | |
| 2025-11-17 | Novartis Pharmaceuticals Corporation | $29 | Food and Beverage | In-kind items and services | SCEMBLIX Drug, Oncology | 2025 | |
| 2025-11-10 | Tempus AI, Inc | $27 | Food and Beverage | In-kind items and services | XT CDX Device, ONCOLOGY | 2025 | |
| 2025-10-27 | Novartis Pharmaceuticals Corporation | $18 | Food and Beverage | In-kind items and services | Fabhalta Drug, Immunology | 2025 | |
| 2025-10-23 | PFIZER INC. | $22 | Food and Beverage | In-kind items and services | IBRANCE Drug, ONCOLOGY | 2025 | |
| 2025-10-18 | Genmab U.S., Inc. | $12 | Food and Beverage | In-kind items and services | Epkinly Drug, Oncology | 2025 | |
| 2025-10-03 | Novartis Pharmaceuticals Corporation | $14 | Food and Beverage | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-10-01 | Daiichi Sankyo Inc. | $28 | Food and Beverage | In-kind items and services | DATROWAY Drug, ONCOLOGY | 2025 | |
| 2025-09-25 | Lilly USA, LLC | $25 | Food and Beverage | In-kind items and services | VERZENIO Drug, Oncology | 2025 | |
| 2025-09-18 | Sumitomo Pharma America, Inc. | $17 | Food and Beverage | In-kind items and services | ORGOVYX Drug, PROSTATE CANCER | 2025 | |
| 2025-09-15 | AstraZeneca Pharmaceuticals LP | $30 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-25 | AstraZeneca Pharmaceuticals LP | $25 | Food and Beverage | In-kind items and services | LYNPARZA Drug, Oncology | 2025 | |
| 2025-08-15 | Genmab U.S., Inc. | $25 | Food and Beverage | In-kind items and services | Epkinly Drug, Oncology | 2025 | |
| 2025-08-13 | Adaptive Biotechnologies Corporation | $33 | Food and Beverage | Cash or cash equivalent | clonoSEQ Device, Devices | 2025 | |
| 2025-08-12 | Daiichi Sankyo Inc. | $15 | Food and Beverage | In-kind items and services | Enhertu Drug, ONCOLOGY | 2025 | |
| 2025-08-07 | Regeneron Healthcare Solutions, Inc. | $32 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-07-30 | Incyte Corporation | $24 | Food and Beverage | Cash or cash equivalent | MONJUVI Drug, Oncology | 2025 | |
| 2025-07-24 | Adaptive Biotechnologies Corporation | $33 | Food and Beverage | Cash or cash equivalent | clonoSEQ Device, Devices | 2025 | |
| 2025-07-23 | PFIZER INC. | $32 | Food and Beverage | In-kind items and services | IBRANCE Drug, ONCOLOGY | 2025 | |
| 2025-07-20 | SUN PHARMACEUTICAL INDUSTRIES INC. | $24 | Food and Beverage | In-kind items and services | Odomzo Drug, Oncology | 2025 | |
| 2025-07-14 | GlaxoSmithKline, LLC. | $23 | Food and Beverage | In-kind items and services | OJJAARA Drug, ONCOLOGY | 2025 | |
| 2025-07-02 | Rigel Pharmaceuticals, Inc. | $24 | Food and Beverage | Cash or cash equivalent | TAVALISSE Drug, Hematology | 2025 | |
| 2025-06-26 | PFIZER INC. | $26 | Food and Beverage | In-kind items and services | IBRANCE Drug, ONCOLOGY | 2025 | |
| 2025-06-18 | Daiichi Sankyo Inc. | $22 | Food and Beverage | In-kind items and services | Enhertu Drug, ONCOLOGY | 2025 | |
| 2025-06-16 | AstraZeneca Pharmaceuticals LP | $33 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-10 | Daiichi Sankyo Inc. | $3 | Food and Beverage | In-kind items and services | Enhertu Drug, ONCOLOGY | 2025 | |
| 2025-06-09 | Gilead Sciences, Inc. | $30 | Food and Beverage | In-kind items and services | Trodelvy Drug, ONC | 2025 | |
| 2025-06-09 | Eisai Inc. | $22 | Food and Beverage | In-kind items and services | Lenvima Drug, Oncology | 2025 | |
| 2025-06-04 | Exelixis Inc. | $21 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-02 | Alexion Pharmaceuticals, Inc. | $26 | Food and Beverage | In-kind items and services | ULTOMIRIS Biological, Rare Disease | 2025 | |
| 2025-05-30 | Merck Sharp & Dohme LLC | $26 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-05-28 | JAZZ PHARMACEUTICALS INC. | $29 | Food and Beverage | In-kind items and services | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | 2025 | |
| 2025-05-21 | Merck Sharp & Dohme LLC | $26 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-05-13 | Sumitomo Pharma America, Inc. | $18 | Food and Beverage | In-kind items and services | ORGOVYX Drug, PROSTATE CANCER | 2025 | |
| 2025-05-07 | PUMA BIOTECHNOLOGY, INC. | $28 | Food and Beverage | In-kind items and services | NERLYNX Drug, ONCOLOGY | 2025 | |
| 2025-04-30 | Azurity Pharmaceuticals, Inc. | $34 | Food and Beverage | In-kind items and services | DANZITEN Drug, ONCOLOGY | 2025 | |
| 2025-04-29 | pharmaand GmbH | $21 | Food and Beverage | In-kind items and services | Rubraca Drug, PARP inhibitor | 2025 | |
| 2025-04-29 | TOLMAR, INC. | $21 | Food and Beverage | In-kind items and services | ELIGARD Drug, Prostate Cancer | 2025 | |
| 2025-04-28 | Genentech USA, Inc. | $20 | Food and Beverage | In-kind items and services | Itovebi Biological, BioOncology | 2025 | |
| 2025-04-16 | Celgene Corporation | $19 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-04-09 | AstraZeneca Pharmaceuticals LP | $28 | Food and Beverage | In-kind items and services | CALQUENCE Drug, Oncology | 2025 | |
| 2025-04-07 | Immunocore Limited | $22 | Food and Beverage | In-kind items and services | KIMMTRAK Drug, Oncology | 2025 | |
| 2025-04-04 | ABBVIE INC. | $31 | Food and Beverage | In-kind items and services | IMBRUVICA Drug, ONCOLOGY | 2025 | |
| 2025-03-27 | Alexion Pharmaceuticals, Inc. | $175 | Consulting Fee | Cash or cash equivalent | ULTOMIRIS Biological, Rare Disease | 2025 | |
| 2025-03-27 | TerSera Therapeutics LLC | $29 | Food and Beverage | In-kind items and services | Zoladex Drug, Oncology | 2025 | |
| 2025-03-26 | Merck Sharp & Dohme LLC | $28 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-03-25 | Novartis Pharmaceuticals Corporation | $24 | Food and Beverage | In-kind items and services | SCEMBLIX Drug, Oncology | 2025 | |
| 2025-03-11 | PharmaEssentia USA Corporation | $29 | Food and Beverage | In-kind items and services | BESREMI Drug, Oncology | 2025 | |
| 2025-03-05 | Novartis Pharmaceuticals Corporation | $24 | Food and Beverage | In-kind items and services | Fabhalta Drug, Immunology | 2025 | |
| 2025-03-03 | Novartis Pharmaceuticals Corporation | $31 | Food and Beverage | In-kind items and services | SCEMBLIX Drug, Oncology | 2025 | |
| 2025-03-03 | AstraZeneca Pharmaceuticals LP | $20 | Food and Beverage | In-kind items and services | TAGRISSO Drug, Oncology | 2025 | |
| 2025-02-27 | Deciphera Pharmaceuticals Inc. | $19 | Food and Beverage | In-kind items and services | QINLOCK Drug, ONCOLOGY | 2025 | |
| 2025-02-24 | Gilead Sciences, Inc. | $22 | Food and Beverage | In-kind items and services | Trodelvy Drug, ONC | 2025 | |
| 2025-02-19 | Daiichi Sankyo Inc. | $1,712 | Consulting Fee | Cash or cash equivalent | DATROWAY Drug, ONCOLOGY | 2025 | |
| 2025-02-12 | Acrotech Biopharma Inc. | $15 | Food and Beverage | In-kind items and services | BELEODAQ Drug, ONCOLOGY | 2025 | |
| 2025-02-10 | PFIZER INC. | $26 | Food and Beverage | In-kind items and services | INLYTA Drug, ONCOLOGY | 2025 | |
| 2025-02-05 | Daiichi Sankyo Inc. | $24 | Food and Beverage | In-kind items and services | Enhertu Drug, ONCOLOGY | 2025 | |
| 2025-02-05 | Janssen Biotech, Inc. | $13 | Food and Beverage | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-02-03 | Janssen Biotech, Inc. | $14 | Food and Beverage | In-kind items and services | DARZALEX Biological, Oncology | 2025 | |
| 2025-01-28 | Acrotech Biopharma Inc. | $18 | Food and Beverage | In-kind items and services | BELEODAQ Drug, ONCOLOGY | 2025 | |
| 2025-01-24 | ARRAY BIOPHARMA INC | $17 | Food and Beverage | In-kind items and services | LORBRENA Drug, ONCOLOGY | 2025 | |
| 2025-01-22 | ADC THERAPEUTICS AMERICA, INC. | $17 | Food and Beverage | Cash or cash equivalent | ZYNLONTA Drug, ONCOLOGY | 2025 | |
| 2025-01-20 | BeiGene USA, Inc. | $27 | Food and Beverage | In-kind items and services | TEVIMBRA Drug, Oncology | 2025 | |
| 2025-01-14 | Gilead Sciences, Inc. | $16 | Food and Beverage | In-kind items and services | Trodelvy Drug, ONC | 2025 | |
| 2025-01-09 | Daiichi Sankyo Inc. | $5 | Food and Beverage | In-kind items and services | Enhertu Drug, ONCOLOGY | 2025 | |
| 2025-01-06 | E.R. Squibb & Sons, L.L.C. | $20 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2024-12-27 | Eisai Inc. | $20 | Food and Beverage | In-kind items and services | Lenvima Drug, Oncology | 2024 | |
| 2024-12-18 | Novartis Pharmaceuticals Corporation | $23 | Food and Beverage | In-kind items and services | SCEMBLIX Drug, Oncology | 2024 | |
| 2024-12-16 | E.R. Squibb & Sons, L.L.C. | $19 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2024 | |
| 2024-12-12 | AstraZeneca Pharmaceuticals LP | $525 | Consulting Fee | Cash or cash equivalent | Truqap Drug, Oncology | 2024 | |
| 2024-12-11 | Rigel Pharmaceuticals, Inc. | $19 | Food and Beverage | Cash or cash equivalent | Rezlidhia Drug, Acute Myeloid Leukemia | 2024 | |
| 2024-12-11 | E.R. Squibb & Sons, L.L.C. | $19 | Food and Beverage | Cash or cash equivalent | 2024 | ||
| 2024-12-10 | Regeneron Healthcare Solutions, Inc. | $17 | Education | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2024 | |
| 2024-12-02 | Blueprint Medicines Corporation | $35 | Food and Beverage | Cash or cash equivalent | AYVAKIT Drug, Oncology / Rare Diseases | 2024 | |
| 2024-11-26 | BeiGene USA, Inc. | $675 | Consulting Fee | Cash or cash equivalent | BRUKINSA Drug, Oncology | 2024 | |
| 2024-11-22 | PFIZER INC. | $19 | Food and Beverage | In-kind items and services | INLYTA Drug, ONCOLOGY | 2024 | |
| 2024-11-20 | Novartis Pharmaceuticals Corporation | $23 | Food and Beverage | In-kind items and services | SCEMBLIX Drug, Oncology | 2024 | |
| 2024-11-18 | Karyopharm Therapeutics Inc. | $24 | Food and Beverage | In-kind items and services | XPOVIO Drug, Oncology | 2024 | |
| 2024-11-07 | ARRAY BIOPHARMA INC | $14 | Food and Beverage | In-kind items and services | LORBRENA Drug, ONCOLOGY | 2024 | |
| 2024-11-06 | Daiichi Sankyo Inc. | $2,740 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-11-06 | Daiichi Sankyo Inc. | $1,370 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-11-01 | Daiichi Sankyo Inc. | $24 | Food and Beverage | In-kind items and services | Enhertu Drug, ONCOLOGY | 2024 | |
| 2024-10-30 | AstraZeneca Pharmaceuticals LP | $525 | Consulting Fee | Cash or cash equivalent | IMFINZI Biological, Oncology | 2024 | |
| 2024-10-30 | AstraZeneca Pharmaceuticals LP | $525 | Consulting Fee | Cash or cash equivalent | IMFINZI Biological, Oncology | 2024 | |
| 2024-10-25 | Merck Sharp & Dohme LLC | $33 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2024 | |
| 2024-10-25 | Genentech USA, Inc. | $19 | Food and Beverage | In-kind items and services | Columvi Biological, BioOncology | 2024 | |
| 2024-10-23 | Coherus Oncology, Inc. | $20 | Food and Beverage | In-kind items and services | Udenyca Biological, Granulocyte colony stimulating factor | 2024 | |
| 2024-10-21 | AstraZeneca Pharmaceuticals LP | $28 | Food and Beverage | In-kind items and services | TAGRISSO Drug, Oncology | 2024 | |
| 2024-10-18 | Incyte Corporation | $26 | Food and Beverage | Cash or cash equivalent | MONJUVI Drug, Oncology | 2024 | |
| 2024-10-16 | ABBVIE INC. | $33 | Food and Beverage | In-kind items and services | IMBRUVICA Drug, ONCOLOGY | 2024 | |
| 2024-10-01 | AstraZeneca Pharmaceuticals LP | $525 | Consulting Fee | Cash or cash equivalent | IMFINZI Biological, Oncology | 2024 | |
| 2024-09-16 | Novartis Pharmaceuticals Corporation | $22 | Food and Beverage | In-kind items and services | LUTATHERA Drug, Oncology | 2024 | |
| 2024-09-11 | Daiichi Sankyo Inc. | $28 | Food and Beverage | In-kind items and services | Enhertu Drug, ONCOLOGY | 2024 | |
| 2024-09-04 | Bayer Healthcare Pharmaceuticals Inc. | $22 | Food and Beverage | In-kind items and services | Nubeqa Drug, Oncology | 2024 | |
| 2024-08-26 | AstraZeneca Pharmaceuticals LP | $525 | Consulting Fee | Cash or cash equivalent | LYNPARZA Drug, Oncology | 2024 | |
| 2024-08-23 | Bayer Healthcare Pharmaceuticals Inc. | $14 | Food and Beverage | In-kind items and services | Stivarga Drug, Oncology | 2024 | |
| 2024-08-21 | GlaxoSmithKline, LLC. | $32 | Food and Beverage | In-kind items and services | JEMPERLI Biological, ONCOLOGY | 2024 | |
| 2024-08-21 | ABBVIE INC. | $26 | Food and Beverage | In-kind items and services | ELAHERE Drug, ONCOLOGY | 2024 | |
| 2024-08-12 | PFIZER INC. | $150 | Consulting Fee | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | 2024 | |
| 2024-08-12 | AstraZeneca Pharmaceuticals LP | $24 | Food and Beverage | In-kind items and services | ENHERTU Biological, Oncology | 2024 | |
| 2024-08-08 | Regeneron Healthcare Solutions, Inc. | $17 | Education | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2024 | |
| 2024-08-06 | Daiichi Sankyo Inc. | $20 | Food and Beverage | In-kind items and services | Enhertu Drug, ONCOLOGY | 2024 | |
| 2024-08-05 | Janssen Biotech, Inc. | $24 | Food and Beverage | In-kind items and services | TECVAYLI Biological, Oncology | 2024 | |
| 2024-08-01 | AstraZeneca Pharmaceuticals LP | $525 | Consulting Fee | Cash or cash equivalent | IMFINZI Biological, Oncology | 2024 | |
| 2024-07-31 | Astellas Pharma US Inc | $27 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-07-22 | Immunocore Limited | $19 | Food and Beverage | In-kind items and services | KIMMTRAK Drug, Oncology | 2024 | |
| 2024-07-15 | PFIZER INC. | $24 | Food and Beverage | In-kind items and services | IBRANCE Drug, ONCOLOGY | 2024 | |
| 2024-07-09 | PFIZER INC. | $18 | Food and Beverage | In-kind items and services | PADCEV Biological, Oncology | 2024 | |
| 2024-07-08 | ARRAY BIOPHARMA INC | $1 | Food and Beverage | In-kind items and services | TUKYSA Drug, Oncology | 2024 | |
| 2024-07-02 | AstraZeneca Pharmaceuticals LP | $525 | Consulting Fee | Cash or cash equivalent | TAGRISSO Drug, Oncology | 2024 | |
| 2024-07-01 | AstraZeneca Pharmaceuticals LP | $28 | Food and Beverage | In-kind items and services | ENHERTU Biological, Oncology | 2024 | |
| 2024-06-25 | AstraZeneca Pharmaceuticals LP | $525 | Consulting Fee | Cash or cash equivalent | IMFINZI Biological, Oncology | 2024 | |
| 2024-06-10 | E.R. Squibb & Sons, L.L.C. | $16 | Food and Beverage | Cash or cash equivalent | 2024 | ||
| 2024-06-04 | Gilead Sciences, Inc. | $26 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-05-28 | SOBI, INC | $16 | Food and Beverage | In-kind items and services | DOPTELET Drug, HEMATOLOGY/ONCOLOGY | 2024 | |
| 2024-05-22 | AstraZeneca Pharmaceuticals LP | $525 | Consulting Fee | Cash or cash equivalent | IMFINZI Biological, Oncology | 2024 | |
| 2024-05-22 | Novartis Pharmaceuticals Corporation | $12 | Food and Beverage | In-kind items and services | KISQALI Drug, Oncology | 2024 | |
| 2024-05-22 | Novartis Pharmaceuticals Corporation | $8 | Food and Beverage | In-kind items and services | KISQALI Drug, Oncology | 2024 | |
| 2024-05-20 | PFIZER INC. | $23 | Food and Beverage | In-kind items and services | ELREXFIO Drug, ONCOLOGY | 2024 | |
| 2024-05-17 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | LUPRON DEPOT Drug, ENDOCRINOLOGY | 2024 | |
| 2024-05-15 | Novartis Pharmaceuticals Corporation | $18 | Food and Beverage | In-kind items and services | Fabhalta Drug, Immunology | 2024 | |
| 2024-05-15 | Genentech USA, Inc. | $13 | Food and Beverage | In-kind items and services | Alecensa Biological, BioOncology | 2024 | |
| 2024-05-14 | Mirati Therapeutics, Inc. | $21 | Food and Beverage | Cash or cash equivalent | KRAZATI Drug, Oncology | 2024 | |
| 2024-05-08 | Lilly USA, LLC | $26 | Food and Beverage | In-kind items and services | VERZENIO Drug, Oncology | 2024 | |
| 2024-05-03 | Janssen Biotech, Inc. | $21 | Food and Beverage | In-kind items and services | TECVAYLI Biological, Oncology | 2024 | |
| 2024-05-02 | Karyopharm Therapeutics Inc. | $30 | Food and Beverage | In-kind items and services | XPOVIO Drug, Oncology | 2024 | |
| 2024-04-26 | Blueprint Medicines Corporation | $1,008 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-04-25 | PFIZER INC. | $20 | Food and Beverage | In-kind items and services | BOSULIF Drug, METABOLIC DISEASE;ONCOLOGY | 2024 | |
| 2024-04-24 | PFIZER INC. | $23 | Food and Beverage | In-kind items and services | XTANDI Drug, ONCOLOGY | 2024 | |
| 2024-04-18 | AstraZeneca Pharmaceuticals LP | $350 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-04-18 | Genentech USA, Inc. | $28 | Food and Beverage | In-kind items and services | Columvi Biological, BioOncology | 2024 | |
| 2024-04-01 | Genentech USA, Inc. | $18 | Food and Beverage | In-kind items and services | Venclexta Biological, BioOncology | 2024 | |
| 2024-03-26 | Daiichi Sankyo Inc. | $26 | Food and Beverage | In-kind items and services | Enhertu Drug, ONCOLOGY | 2024 | |
| 2024-03-22 | Janssen Biotech, Inc. | $15 | Food and Beverage | In-kind items and services | DARZALEX Biological, Oncology | 2024 | |
| 2024-03-21 | Pharmacosmos Therapeutics Inc. | $22 | Travel and Lodging | Cash or cash equivalent | MONOFERRIC Drug, HEMATOLOGY | 2024 | |
| 2024-03-21 | Pharmacosmos Therapeutics Inc. | $22 | Travel and Lodging | Cash or cash equivalent | MONOFERRIC Drug, HEMATOLOGY | 2024 | |
| 2024-03-21 | Pharmacosmos Therapeutics Inc. | $21 | Food and Beverage | Cash or cash equivalent | MONOFERRIC Drug, HEMATOLOGY | 2024 | |
| 2024-03-21 | Pharmacosmos Therapeutics Inc. | $12 | Travel and Lodging | Cash or cash equivalent | MONOFERRIC Drug, HEMATOLOGY | 2024 | |
| 2024-03-21 | Pharmacosmos Therapeutics Inc. | $12 | Travel and Lodging | Cash or cash equivalent | MONOFERRIC Drug, HEMATOLOGY | 2024 | |
| 2024-03-21 | Pharmacosmos Therapeutics Inc. | $5 | Food and Beverage | Cash or cash equivalent | MONOFERRIC Drug, HEMATOLOGY | 2024 | |
| 2024-03-20 | Coherus Oncology, Inc. | $24 | Food and Beverage | In-kind items and services | Udenyca Biological, Granulocyte colony stimulating factor | 2024 | |
| 2024-03-13 | E.R. Squibb & Sons, L.L.C. | $16 | Food and Beverage | Cash or cash equivalent | 2024 | ||
| 2024-03-12 | Pharmacosmos Therapeutics Inc. | $1,500 | Honoraria | Cash or cash equivalent | MONOFERRIC Drug, HEMATOLOGY | 2024 | |
| 2024-03-12 | Lilly USA, LLC | $28 | Food and Beverage | In-kind items and services | VERZENIO Drug, Oncology | 2024 | |
| 2024-03-11 | Rigel Pharmaceuticals, Inc. | $17 | Food and Beverage | Cash or cash equivalent | Rezlidhia Drug, Acute Myeloid Leukemia | 2024 | |
| 2024-03-06 | AstraZeneca Pharmaceuticals LP | $525 | Consulting Fee | Cash or cash equivalent | IMFINZI Biological, Oncology | 2024 | |
| 2024-03-06 | Novartis Pharmaceuticals Corporation | $23 | Food and Beverage | In-kind items and services | Fabhalta Drug, Immunology | 2024 | |
| 2024-02-26 | Eisai Inc. | $23 | Food and Beverage | In-kind items and services | Lenvima Drug, Oncology | 2024 | |
| 2024-02-05 | Novartis Pharmaceuticals Corporation | $32 | Food and Beverage | In-kind items and services | KISQALI Drug, Oncology | 2024 | |
| 2024-02-03 | Pharmacosmos Therapeutics Inc. | $179 | Travel and Lodging | In-kind items and services | MONOFERRIC Drug, HEMATOLOGY | 2024 | |
| 2024-02-03 | Pharmacosmos Therapeutics Inc. | $174 | Travel and Lodging | In-kind items and services | MONOFERRIC Drug, HEMATOLOGY | 2024 | |
| 2024-02-03 | Pharmacosmos Therapeutics Inc. | $83 | Food and Beverage | In-kind items and services | MONOFERRIC Drug, HEMATOLOGY | 2024 | |
| 2024-02-03 | Pharmacosmos Therapeutics Inc. | $75 | Food and Beverage | In-kind items and services | MONOFERRIC Drug, HEMATOLOGY | 2024 | |
| 2024-02-03 | Pharmacosmos Therapeutics Inc. | $59 | Food and Beverage | In-kind items and services | MONOFERRIC Drug, HEMATOLOGY | 2024 | |
| 2024-02-02 | Pharmacosmos Therapeutics Inc. | $481 | Travel and Lodging | In-kind items and services | MONOFERRIC Drug, HEMATOLOGY | 2024 | |
| 2024-02-02 | Pharmacosmos Therapeutics Inc. | $394 | Travel and Lodging | In-kind items and services | MONOFERRIC Drug, HEMATOLOGY | 2024 | |
| 2024-01-25 | AstraZeneca Pharmaceuticals LP | $24 | Food and Beverage | In-kind items and services | LYNPARZA Drug, Oncology | 2024 | |
| 2024-01-19 | Lilly USA, LLC | $13 | Food and Beverage | In-kind items and services | VERZENIO Drug, Oncology | 2024 | |
| 2024-01-09 | Janssen Biotech, Inc. | $22 | Food and Beverage | In-kind items and services | DARZALEX Biological, Oncology | 2024 | |
| 2024-01-03 | AstraZeneca Pharmaceuticals LP | $22 | Food and Beverage | In-kind items and services | ENHERTU Biological, Oncology | 2024 | |
| 2023-12-29 | Pharmacyclics LLC, an AbbVie Company | $31 | Food and Beverage | In-kind items and services | IMBRUVICA Drug, ONCOLOGY | 2023 | |
| 2023-12-14 | AstraZeneca Pharmaceuticals LP | $21 | Food and Beverage | In-kind items and services | ENHERTU Biological, Oncology | 2023 | |
| 2023-12-11 | E.R. Squibb & Sons, L.L.C. | $15 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2023 | |
| 2023-12-04 | Daiichi Sankyo Inc. | $360 | Honoraria | Cash or cash equivalent | 2023 | ||
| 2023-12-01 | Gilead Sciences, Inc. | $24 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-11-29 | Immunocore Limited | $19 | Food and Beverage | In-kind items and services | KIMMTRAK Drug, Oncology | 2023 | |
| 2023-11-07 | Astellas Pharma US Inc | $22 | Food and Beverage | In-kind items and services | Padcev Drug, Oncology | 2023 | |
| 2023-10-25 | Daiichi Sankyo Inc. | $29 | Food and Beverage | In-kind items and services | INJECTAFER Drug, Iron Deficiency Anemia | 2023 | |
| 2023-10-09 | Merck Sharp & Dohme LLC | $34 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2023 | |
| 2023-09-22 | Genentech USA, Inc. | $24 | Food and Beverage | In-kind items and services | Venclexta Biological, BioOncology | 2023 | |
| 2023-09-21 | Mirati Therapeutics, Inc. | $18 | Food and Beverage | In-kind items and services | KRAZATI Drug, ONCOLOGY | 2023 | |
| 2023-08-30 | Foundation Medicine, Inc. | $37 | Food and Beverage | In-kind items and services | FOUNDATIONONE LIQUID CDX Device, Oncology | 2023 | |
| 2023-08-25 | PFIZER INC. | $13 | Food and Beverage | In-kind items and services | IBRANCE Drug, ONCOLOGY | 2023 | |
| 2023-07-27 | AstraZeneca Pharmaceuticals LP | $525 | Consulting Fee | Cash or cash equivalent | CALQUENCE Drug, Oncology | 2023 | |
| 2023-06-20 | Novartis Pharmaceuticals Corporation | $16 | Food and Beverage | In-kind items and services | PLUVICTO Drug, Oncology | 2023 | |
| 2023-06-13 | Novartis Pharmaceuticals Corporation | $29 | Food and Beverage | In-kind items and services | KISQALI Drug, Oncology | 2023 | |
| 2023-03-31 | GlaxoSmithKline, LLC. | $21 | Food and Beverage | In-kind items and services | SHINGRIX Biological, VACCINES | 2023 | |
| 2023-03-01 | Daiichi Sankyo Inc. | $200 | Honoraria | Cash or cash equivalent | 2023 | ||
| 2022-05-26 | GlaxoSmithKline, LLC. | $430 | Consulting Fee | Cash or cash equivalent | BLENREP Biological, ONCOLOGY | 2022 | |
| 2022-04-22 | Regeneron Healthcare Solutions, Inc. | $23 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2022 | |
| 2022-01-19 | Novocure GmbH | $200 | Honoraria | Cash or cash equivalent | 2022 | ||
| 2021-09-09 | G1 Therapeutics, Inc. | $14 | Food and Beverage | Cash or cash equivalent | COSELA Drug, ONCOLOGY | 2021 | |
| 2021-08-17 | GlaxoSmithKline, LLC. | $975 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-06-22 | EMD Serono, Inc. | $500 | Consulting Fee | Cash or cash equivalent | Tepmetko Drug, Oncology | 2021 | |
| 2021-04-27 | GlaxoSmithKline, LLC. | $104 | Food and Beverage | In-kind items and services | ZEJULA Drug, ONCOLOGY | 2021 | |
| 2021-04-22 | E.R. Squibb & Sons, L.L.C. | $1,030 | Consulting Fee | Cash or cash equivalent | OPDIVO Biological, Oncology | 2021 | |
| 2021-03-22 | Karyopharm Therapeutics Inc. | $1,550 | Consulting Fee | Cash or cash equivalent | XPOVIO Drug, Oncology | 2021 | |
| 2021-01-26 | GlaxoSmithKline, LLC. | $1 | Food and Beverage | In-kind items and services | BLENREP Biological, ONCOLOGY | 2021 | |
| 2020-09-09 | Regeneron Healthcare Solutions, Inc. | $33 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2020 | |
| 2020-07-14 | GlaxoSmithKline, LLC. | $57 | Food and Beverage | In-kind items and services | ZEJULA Drug, ONCOLOGY | 2020 | |
| 2020-04-20 | SEAGEN INC. | $1,441 | Consulting Fee | Cash or cash equivalent | PADCEV Biological, Oncology | 2020 | |
| 2020-03-04 | AstraZeneca Pharmaceuticals LP | $13 | Food and Beverage | In-kind items and services | CALQUENCE Drug, Oncology | 2020 | |
| 2020-02-11 | AstraZeneca Pharmaceuticals LP | $115 | Food and Beverage | In-kind items and services | LYNPARZA Drug, Oncology | 2020 | |
| 2019-12-13 | EMD Serono, Inc. | $19 | Food and Beverage | In-kind items and services | Bavencio Biological, Oncology | 2019 |
The latest 200 records of 204.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2023-03-06 | Roche Products Limited | Radiation Therapy Services Psc | $70,800 | Safety and efficacy of Venetoclax Fulvestrant in ER positive Metastatic Breast Cancer | 2023 |
| 2023-02-23 | Genentech, Inc. | RADIATION THERAPY SERVICES PSC ASHLAND BELLEFONTE CANCER CENTER | $24,698 | GDC 9545 vs single agent endocrine therapy of physician s choice in HR 2L 3L mBC | 2023 |
| 2021-09-16 | Roche Products Limited | RADIATION THERAPU SERVICES | $2,459 | SAFETY AND EFFICACY OF VENETOCLAX FULVESTRANT IN ER POSITIVE METASTATIC BREAST CANCER | 2021 |
| 2021-07-20 | Roche Products Limited | RADIATION THERAPU SERVICES | $105 | SAFETY AND EFFICACY OF VENETOCLAX FULVESTRANT IN ER POSITIVE METASTATIC BREAST CANCER | 2021 |
| 2021-05-26 | PFIZER INC. | RADIATION THERAPY SERVICE PSC | $51,346 | A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY CISPLATIN PLUS | 2021 |
| 2021-01-26 | Roche Products Limited | RADIATION THERAPU SERVICES | $3,405 | SAFETY AND EFFICACY OF VENETOCLAX FULVESTRANT IN ER POSITIVE METASTATIC BREAST CANCER | 2021 |
| 2020-10-22 | Roche Products Limited | RADIATION THERAPU SERVICES | $14,205 | SAFETY AND EFFICACY OF VENETOCLAX FULVESTRANT IN ER POSITIVE METASTATIC BREAST CANCER | 2020 |
| 2020-06-17 | PFIZER INC. | RADIATION THERAPY SERVICE PSC | $32,775 | A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY CISPLATIN PLUS | 2020 |
| 2020-05-11 | Roche Products Limited | RADIATION THERAPU SERVICES | $4,422 | SAFETY AND EFFICACY OF VENETOCLAX FULVESTRANT IN ER POSITIVE METASTATIC BREAST CANCER | 2020 |
| 2020-05-05 | Dova Pharmaceuticals | OUR LADY OF BELLEFONTE | $5,826 | Phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of avatrombopag in subjec | 2020 |
| 2020-05-05 | Dova Pharmaceuticals | OUR LADY OF BELLEFONTE | $3,500 | Phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of avatrombopag in subjec | 2020 |
| 2020-05-05 | Dova Pharmaceuticals | OUR LADY OF BELLEFONTE | $5,150 | Phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of avatrombopag in subjec | 2020 |
| 2020-01-29 | Dova Pharmaceuticals | OUR LADY OF BELLEFONTE | $637 | Phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of avatrombopag in subjec | 2020 |
| 2020-01-15 | PFIZER INC. | RADIATION THERAPY SERVICE PSC | $79,827 | A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY CISPLATIN PLUS | 2020 |
| 2019-12-17 | Dova Pharmaceuticals | OUR LADY OF BELLEFONTE | $7,606 | Phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of avatrombopag in subjec | 2019 |
| 2019-12-10 | PFIZER INC. | RADIATION THERAPY SERVICE PSC | $204 | A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY CISPLATIN PLUS | 2019 |
| 2019-07-02 | Dova Pharmaceuticals | OUR LADY OF BELLEFONTE | $8,489 | Phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of avatrombopag in subjec | 2019 |
| 2019-04-29 | ABBVIE INC. | Radiation Therapy Services Inc | $3,732 | M16-298 | 2019 |
| 2019-04-01 | ABBVIE INC. | Radiation Therapy Services Inc | $2,182 | M16-298 | 2019 |
| 2019-02-28 | ABBVIE INC. | Radiation Therapy Services Inc | $4,425 | M16-298 | 2019 |
| 2019-02-07 | PFIZER INC. | RADIATION THERAPY SERVICE PSC | $58,573 | A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY CISPLATIN PLUS | 2019 |
| 2019-01-29 | ABBVIE INC. | Radiation Therapy Services Inc | $3,693 | M16-298 | 2019 |
| 2019-01-16 | Dova Pharmaceuticals | OUR LADY OF BELLEFONTE | $8,500 | Phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of avatrombopag in subjec | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Douglasville, GA, county Douglas County, GA, state Georgia; placed by its city name.
| Measure | Place (city or town) Douglasville, GA | County Douglas County, GA | State Georgia |
|---|---|---|---|
| Population B01003 | 37,536 | 147,888 | 10,940,407 |
| Population, 2020 census P1 | 34,650 | 144,237 | 10,711,908 |
| Median age B01002 | 36.2 | 36.9 | 37.6 |
| Under 18 B01001 | 26.4% | 25.3% | 23.2% |
| 65 and over B01001 | 11.4% | 12.2% | 15.0% |
| Households B11001 | 14,104 | 52,079 | 4,074,366 |
| Foreign born B05002 | 7.6% | 9.6% | 11.2% |
| Median household income B19013 | $79,107 | $82,984 | $77,353 |
| Median family income B19113 | $90,081 | $91,657 | $93,754 |
| Per capita income B19301 | $37,548 | $36,042 | $40,924 |
| Poverty rate B17001 | 10.7% | 10.9% | 13.4% |
| Unemployment rate B23025 | 6.0% | 6.2% | 5.1% |
| Civilian labor force B23025 | 19,982 | 76,037 | 5,496,061 |
| Mean commute (minutes) B08013 | 32.7 | 33.2 | 28.3 |
| Bachelor's degree or higher B15003 | 35.2% | 30.8% | 34.9% |
| Housing units B25001 | 15,356 | 56,187 | 4,541,835 |
| Owner-occupied B25003 | 48.3% | 66.9% | 65.7% |
| Renters B25003 | 51.7% | 33.1% | 34.3% |
| Median home value B25077 | $359,200 | $296,900 | $303,300 |
| Median gross rent B25064 | $1,582 | $1,570 | $1,393 |
| White, not Hispanic B03002 | 20.1% | 31.1% | 49.1% |
| Black B03002 | 65.7% | 49.2% | 30.7% |
| Hispanic or Latino B03002 | 7.5% | 12.2% | 11.0% |
| Asian B03002 | 1.8% | 1.8% | 4.5% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Economy now FRED unemployment 3.3% in Sep 2026 (3.4% a year earlier); per capita personal income $65,111 in 2025, up 26% in five years (+1.6% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Douglasville, GA.
Comments